These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22972494)

  • 1. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
    Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
    Yang YA; Dukhanina O; Tang B; Mamura M; Letterio JJ; MacGregor J; Patel SC; Khozin S; Liu ZY; Green J; Anver MR; Merlino G; Wakefield LM
    J Clin Invest; 2002 Jun; 109(12):1607-15. PubMed ID: 12070308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
    Gorelik L; Flavell RA
    Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
    Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
    Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
    Foster AE; Dotti G; Lu A; Khalil M; Brenner MK; Heslop HE; Rooney CM; Bollard CM
    J Immunother; 2008 Jun; 31(5):500-5. PubMed ID: 18463534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway.
    Grainger JR; Smith KA; Hewitson JP; McSorley HJ; Harcus Y; Filbey KJ; Finney CA; Greenwood EJ; Knox DP; Wilson MS; Belkaid Y; Rudensky AY; Maizels RM
    J Exp Med; 2010 Oct; 207(11):2331-41. PubMed ID: 20876311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
    Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
    J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta antagonists: why suppress a tumor suppressor?
    Akhurst RJ
    J Clin Invest; 2002 Jun; 109(12):1533-6. PubMed ID: 12070299
    [No Abstract]   [Full Text] [Related]  

  • 15. [Better tumor eradication in transgenic altered T-lymphocytes. Role of the TGF-beta signal transduction cascade].
    Hautarzt; 2001 Dec; 52(12):1135-6. PubMed ID: 11910867
    [No Abstract]   [Full Text] [Related]  

  • 16. The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.
    Quatromoni JG; Suzuki E; Okusanya O; Judy BF; Bhojnagarwala P; Venegas O; Eruslanov E; Predina JD; Albelda SM; Singhal S
    BMC Immunol; 2013 Jul; 14():30. PubMed ID: 23865808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
    Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
    Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.
    Bollard CM; Rössig C; Calonge MJ; Huls MH; Wagner HJ; Massague J; Brenner MK; Heslop HE; Rooney CM
    Blood; 2002 May; 99(9):3179-87. PubMed ID: 11964281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated form of TGF-βRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice.
    Ishigame H; Mosaheb MM; Sanjabi S; Flavell RA
    J Immunol; 2013 Jun; 190(12):6340-50. PubMed ID: 23686479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.
    Ryzhov SV; Pickup MW; Chytil A; Gorska AE; Zhang Q; Owens P; Feoktistov I; Moses HL; Novitskiy SV
    J Immunol; 2014 Sep; 193(6):3155-64. PubMed ID: 25127858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.